Performance evaluation of the BD SARS-CoV-2 reagents for the BD MAX™ system

Competing Interest Statement

KY, WL, LN, EL, and CKC are employees of Becton, Dickinson and Company. All authors declare no conflicts of interest.

Clinical Trial

Registration of this study at ClinicalTrials.gov was not obtained as it did not fulfill the applicable minimum medical device clinical trial requirement criteria as per the Food and Drug Administration Amendments Act. Specifically, this study did not assess health outcomes associated with the use of this assay.

Funding Statement

This study was funded by Becton, Dickinson and Company, BD Life Sciences - Integrated Diagnostic Solutions. Non-BD employee authors received research funds to support their work for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Advarra Institutional Review Board.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes